Life Sciences Partners portfolio company IDEA AG has agreed to sign a $202m licensing deal with an affiliate of American pharmaceutical Alpharma . The agreement involves the licensing of exclusive United States rights to Diractin as a prescription topical NSAID (non-steroidal anti-inflammatory drug) in the US. The license also includes access to IDEA's Transfersome technology platform for local drug delivery to targeted peripheral areas of the body. The payment will be made in several steps, subject to the results of clinical trials and US product approval.
CIC is also fundraising for CIC Mezzanine & Unitranche 5, which launched in September and held a first closing on €150m
Round is one of the largest venture capital deals in Germany this year
Berthoux and Desmottes join as operating partners, while Philips becomes a strategic partner
Vitrulan has acquired the business for its broader product range and to expand internationally